Text Size

Pediatric Epilepsy Study

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Novartis ( Novartis Pharmaceuticals )
ClinicalTrials.gov Identifier:
NCT00050934
First received: December 30, 2002
Last updated: November 22, 2011
Last verified: November 2011
History of Changes
  Purpose

This study will evaluate the safety and effectiveness of oxcarbazepine (Trileptal) as add-on therapy in the treatment of partial seizures in pediatric patients 1 month to 3 years of age.


Condition Intervention Phase
Epilepsy
Epilepsies, Partial
 Drug: oxcarbazepine
 Phase 3

Study Type: Interventional
Study Design: Endpoint Classification: Safety/Efficacy Study
Primary Purpose: Treatment
Official Title: A Multicenter, Rater-blind, Randomized, Age-stratified, Parallel-group Study Comparing Two Doses of Oxcarbazepine as Adjunctive Therapy in Pediatric Patients With Inadequately-controlled Partial Seizures.

Resource links provided by NLM:

MedlinePlus related topics: Epilepsy Seizures
U.S. FDA Resources

Further study details as provided by Novartis:

Primary Outcome Measures:
  • change in seizure frequency/24 hours (during the last 72 hours in the Treatment Phase compared to Baseline)

Secondary Outcome Measures:
  • % change in seizure frequency/24 hours; change in seizure frequency/24 hours; response to treatment (at least a 50%, 75%, or 100% reduction seizure frequency/24 hours).

Enrollment: 132
Study Start Date: June 2002
Study Completion Date: June 2004
Primary Completion Date: June 2004 (Final data collection date for primary outcome measure)
  Eligibility

Ages Eligible for Study:   1 Month to 3 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

INCLUSION CRITERIA: To enter this study, patients must:

  • Have a diagnosis of partial seizures
  • Be willing to be hospitalized
  • Weigh a minimum of 6.6 pounds
  • Be taking a stable dose of one to two concomitant anti-epileptic medications
  • Have had a previous CAT scan/MRI confirming the absence of space occupying lesions or progressive neurological disease
  • Have normal laboratory results

EXCLUSION CRITERIA: To enter this study, a patient must not have or be:

  • Seizures caused by metabolic disturbance, toxic exposure, or active infection
  • A primary diagnosis of generalized epilepsy (exception - secondarily generalized seizures)
  • A history of status epilepticus within 30 days
  • Seizures not related to epilepsy
  • Frequent use of additional anti-epileptic medications to treat increases in seizures (for example: rectal diazepam)
  • Taking felbamate within 6 months
  • Serum sodium levels <135 mEq/L
  • Significant heart, breathing, kidney, stomach, liver, blood, or cancer disorder requiring treatment/therapy
  • A history of chronic infection (e.g., hepatitis or HIV)
  • Significant electrocardiogram (ECG) abnormalities
  • A nursing mother taking anti-convulsant drugs
  • Previously demonstrated sensitivity/allergic reaction to Trileptal or related compounds
  • Used experimental medication within 30 days of entering this study
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00050934

  Hide Study Locations
Locations
United States, Alabama
Birmingham, Alabama, United States, 35233
Mobile, Alabama, United States, 36693
United States, California
Los Angeles, California, United States, 90027
Los Angeles, California, United States, 90095
Madera, California, United States, 93638
Orange, California, United States, 92868
United States, Delaware
Wilmington, Delaware, United States, 19806
United States, Florida
Miami, Florida, United States, 33155
Tampa, Florida, United States, 33607
United States, Georgia
Atlanta, Georgia, United States, 30342
United States, Idaho
Boise, Idaho, United States, 83712
United States, Michigan
Ann Arbor, Michigan, United States, 48109
United States, Minnesota
Duluth, Minnesota, United States, 55805
St. Paul, Minnesota, United States, 55102
United States, Missouri
Chesterfields, Missouri, United States, 63017
United States, New York
Buffalo, New York, United States, 14222
New York, New York, United States, 10016
New York, New York, United States, 10032
United States, Ohio
Akron, Ohio, United States, 44308
Cincinnati, Ohio, United States, 45229
Cleveland, Ohio, United States, 44106
United States, Oregon
Portland, Oregon, United States, 97201
United States, Pennsylvania
Philadelphia, Pennsylvania, United States, 19104
United States, Texas
Fort Worth, Texas, United States, 76104
Houston, Texas, United States, 77030
United States, Virginia
Norfolk, Virginia, United States, 23507
Brazil
Brigadeiro Hospital
Sao Paulo - SP, Brazil, 01401-901
Germany
Kehl-Kork, Germany, 77694
Kiel, Germany, 24105
Mexico
Novartis
Mexico City, Mexico
Sponsors and Collaborators
Novartis Pharmaceuticals
Investigators
Study Director: Novartis Pharmaceuticals Novartis Pharmaceuticals
  More Information

No publications provided

Responsible Party: Novartis ( Novartis Pharmaceuticals )
ClinicalTrials.gov Identifier: NCT00050934     History of Changes
Other Study ID Numbers: CTRI476E 2340
Study First Received: December 30, 2002
Last Updated: November 22, 2011
Health Authority: United States: Food and Drug Administration

Keywords provided by Novartis:
partial seizures

Additional relevant MeSH terms:
Epilepsy
Epilepsies, Partial
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
 Oxcarbazepine
Anticonvulsants
Central Nervous System Agents
Therapeutic Uses
Pharmacologic Actions

ClinicalTrials.gov processed this record on May 19, 2013